These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 10604231

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.
    Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J.
    Int J Mol Med; 2006 Feb; 17(2):309-17. PubMed ID: 16391831
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Kinetics of phage-mediated biocontrol of bacteria.
    Abedon ST.
    Foodborne Pathog Dis; 2009 Sep; 6(7):807-15. PubMed ID: 19459758
    [Abstract] [Full Text] [Related]

  • 26. Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields.
    Jamal M, Bukhari SMAUS, Andleeb S, Ali M, Raza S, Nawaz MA, Hussain T, Rahman SU, Shah SSA.
    J Basic Microbiol; 2019 Feb; 59(2):123-133. PubMed ID: 30485461
    [Abstract] [Full Text] [Related]

  • 27. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, Clokie MRJ, Garton NJ, Stapley AGF, Kirpichnikova A.
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [Abstract] [Full Text] [Related]

  • 28. Phage cocktails and the future of phage therapy.
    Chan BK, Abedon ST, Loc-Carrillo C.
    Future Microbiol; 2013 Jun; 8(6):769-83. PubMed ID: 23701332
    [Abstract] [Full Text] [Related]

  • 29. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis.
    Golkar Z, Bagasra O, Pace DG.
    J Infect Dev Ctries; 2014 Feb 13; 8(2):129-36. PubMed ID: 24518621
    [Abstract] [Full Text] [Related]

  • 30. Bacteriophage host range and bacterial resistance.
    Hyman P, Abedon ST.
    Adv Appl Microbiol; 2010 Feb 13; 70():217-48. PubMed ID: 20359459
    [Abstract] [Full Text] [Related]

  • 31. A review of models for the therapy of experimental infections.
    Bergeron MG.
    Scand J Infect Dis Suppl; 1978 Feb 13; (14):189-206. PubMed ID: 279972
    [Abstract] [Full Text] [Related]

  • 32. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides.
    Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ.
    J Appl Microbiol; 2008 Jan 13; 104(1):1-13. PubMed ID: 18171378
    [Abstract] [Full Text] [Related]

  • 33. Studies on bacteriophage penetration in patients subjected to phage therapy.
    Weber-Dabrowska B, Dabrowski M, Slopek S.
    Arch Immunol Ther Exp (Warsz); 1987 Jan 13; 35(5):563-8. PubMed ID: 3332066
    [Abstract] [Full Text] [Related]

  • 34. Bacteriophage therapy.
    Summers WC.
    Annu Rev Microbiol; 2001 Jan 13; 55():437-51. PubMed ID: 11544363
    [Abstract] [Full Text] [Related]

  • 35. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM, Gorman SP, Donnelly RF, Gilmore BF.
    J Pharm Pharmacol; 2011 Oct 13; 63(10):1253-64. PubMed ID: 21899540
    [Abstract] [Full Text] [Related]

  • 36. [Phagotherapy: a nightmare for bacteria, a dream for physicians?].
    Debarbieux L, Saussereau E, Maura D.
    Biol Aujourdhui; 2013 Oct 13; 207(3):181-90. PubMed ID: 24330971
    [Abstract] [Full Text] [Related]

  • 37. Bacteriophages as therapeutic agents.
    Sulakvelidze A, Morris JG.
    Ann Med; 2001 Nov 13; 33(8):507-9. PubMed ID: 11730156
    [Abstract] [Full Text] [Related]

  • 38. Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.
    Chanishvili N.
    Curr Drug Deliv; 2016 Nov 13; 13(3):309-23. PubMed ID: 27090515
    [Abstract] [Full Text] [Related]

  • 39. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model.
    Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP, Daly JM.
    Surgery; 2005 Jun 13; 137(6):639-46. PubMed ID: 15933632
    [Abstract] [Full Text] [Related]

  • 40. Antibacterial application of engineered bacteriophage nanomedicines: antibody-targeted, chloramphenicol prodrug loaded bacteriophages for inhibiting the growth of Staphylococcus aureus bacteria.
    Vaks L, Benhar I.
    Methods Mol Biol; 2011 Jun 13; 726():187-206. PubMed ID: 21424451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.